Complete Filing Data
Mereo BioPharma Group plc reported Research And Development Expense of $17.77 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Mereo BioPharma Group plc did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Research And Development Expense | $17.8M | $20.9M | $17.4M | $29.5M | $23.6M | $16.3M | $23.6M | $22.7M | $34.6M |
| Net Income Loss | -$41.9M | -$43.3M | -$29.5M | -$42.2M | |||||
| Other Comprehensive Income Loss Net Of Tax | $8.0M | -$1.4M | $4.2M | -$10.7M | |||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $8.0M | -$1.4M | $4.2M | -$10.7M | |||||
| Operating Income Loss | -$40.1M | -$47.4M | -$28.4M | -$54.4M | |||||
| Interest Expense | $255.0K | $1.4M | $2.9M | $4.2M | |||||
| Income Tax Expense Benefit | $0.00 | $0.00 | -$532.0K | -$718.0K | |||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$41.9M | -$43.3M | -$30.0M | -$42.9M | |||||
| General And Administrative Expense | $23.0M | $26.4M | $18.4M | $26.1M | |||||
| Comprehensive Income Net Of Tax | -$33.9M | -$44.6M | -$25.3M | -$52.9M | |||||
| Benefit From Research And Development Tax Credit | $1.9M | $1.6M | $1.3M | $1.7M | |||||
| Profit Loss Attributable To Owners Of Parent | -$34.2M | $12.7M | -$163.6M | -$34.8M | -$32.0M | -$38.8M | |||
| Revenues | $500.0K | $0.00 | $10.0M | $0.00 | |||||
| Profit Loss From Operating Activities | -$43.6M | -$20.9M | -$37.6M | -$39.5M | -$34.5M | -$45.3M | |||
| Profit Loss Before Tax | -$36.1M | $14.2M | -$166.5M | -$41.1M | -$37.3M | -$47.0M | |||
| Income Tax Expense Continuing Operations | -$1.9M | $1.5M | -$2.8M | -$6.3M | -$5.3M | -$8.2M | |||
| Cost Of Revenues | $133.0K | $0.00 | $2.6M | -$1.1M | |||||
| Comprehensive Income | -$36.0M | $12.5M | -$163.3M | -$35.3M | -$32.0M | -$38.8M | |||
| Other Comprehensive Income | -$1.8M | -$191.0K | $349.0K | -$499.0K | |||||
| Income Taxes Paid Refund Classified As Operating Activities | $1.5M | -$2.8M | -$10.4M | -$1.1M | -$8.2M | -$5.3M | |||
| Research And Development Incentives Receivables Current | $1.5M | $2.8M | $1.2M | $1.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Research And Development Expense | $4.3M | $5.4M | $3.9M | $3.2M | $4.9M | $4.0M | $3.6M | $3.7M | $5.3M |
| Net Income Loss | -$7.0M | -$14.6M | -$12.9M | -$15.0M | -$12.3M | -$9.0M | -$6.5M | -$1.8M | -$12.1M |
| Other Comprehensive Income Loss Net Of Tax | -$2.3M | $6.6M | $3.6M | $7.2M | $5.0K | -$798.0K | -$3.6M | $1.4M | $2.3M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$2.3M | $6.6M | $3.6M | $7.2M | $5.0K | -$798.0K | -$3.6M | $1.4M | $2.3M |
| Operating Income Loss | -$10.0M | -$10.5M | -$11.2M | -$9.4M | -$12.8M | -$9.9M | -$9.1M | -$811.0K | -$11.4M |
| Interest Expense | $28.0K | $24.0K | $180.0K | $353.0K | $331.0K | $310.0K | $700.0K | $1.0M | $800.0K |
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$7.0M | -$14.6M | -$12.9M | -$15.0M | -$12.3M | -$9.0M | -$6.5M | -$1.8M | -$12.1M |
| General And Administrative Expense | $6.0M | $5.5M | $7.3M | $6.2M | $7.9M | $5.9M | $5.7M | $2.7M | $6.5M |
| Comprehensive Income Net Of Tax | -$9.3M | -$8.0M | -$9.3M | -$7.8M | -$12.3M | -$9.7M | -$10.1M | -$351.0K | -$9.8M |
| Benefit From Research And Development Tax Credit | $446.0K | $745.0K | $185.0K | $226.0K | $369.0K | $477.0K | $82.0K | $621.0K | $499.0K |
| Profit Loss Attributable To Owners Of Parent | |||||||||
| Revenues | $0.00 | $500.0K | $0.00 | $0.00 | $0.00 | $0.00 | $9.0M | $0.00 | |
| Profit Loss From Operating Activities | |||||||||
| Profit Loss Before Tax | |||||||||
| Income Tax Expense Continuing Operations | |||||||||
| Cost Of Revenues | $0.00 | $132.0K | $0.00 | $0.00 | $0.00 | -$235.0K | $3.4M | $347.0K | |
| Comprehensive Income | |||||||||
| Other Comprehensive Income | |||||||||
| Income Taxes Paid Refund Classified As Operating Activities | |||||||||
| Research And Development Incentives Receivables Current | $1.0M | $2.8M | $1.9M | $2.4M | $2.0M | $1.6M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $40.9M | $61.0M | $50.5M | $51.4M | $92.2M | |||||
| Liabilities | $5.0M | $15.4M | $16.0M | $26.0M | $38.4M | $77.9M | $46.2M | $34.5M | ||
| Assets | $45.9M | $76.4M | $66.5M | $77.4M | $126.4M | $62.9M | $86.4M | $67.3M | ||
| Equity | $40.9M | $61.0M | $50.5M | $51.4M | $92.2M | |||||
| Cash And Cash Equivalents | $56.3M | $94.3M | $23.5M | $16.3M | $25.0M | $50.0M | $53.6M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $41.0M | $69.8M | $57.4M | $68.2M | $127.4M | |||||
| Intangible Assets Other Than Goodwill | $24.1M | $24.6M | $31.6M | $44.5M | $32.6M | $33.0M | $25.8M | |||
| Property Plant And Equipment | $1.8M | $2.5M | $1.6M | $11.6M | $149.0K | $153.0K | $174.0K | |||
| Retained Earnings | -$331.2M | -$297.0M | -$309.7M | -$146.1M | -$111.2M | -$79.3M | ||||
| Cash Flows From Used In Operating Activities | -$38.8M | -$5.2M | -$28.3M | -$45.9M | -$23.1M | -$32.1M | ||||
| Cash Flows From Used In Investing Activities | $1.5M | -$421.0K | $1.5M | $43.3M | $252.0K | -$3.7M | ||||
| Cash Flows From Used In Financing Activities | -$784.0K | $77.7M | $34.7M | -$5.7M | -$2.1M | $33.7M | ||||
| Adjustments For Increase Decrease In Trade And Other Payables | $1.1M | -$1.3M | -$3.6M | -$6.7M | $1.6M | $3.9M | ||||
| Adjustments For Decrease Increase In Trade And Other Receivables | $695.0K | -$589.0K | $141.0K | -$936.0K | $804.0K | -$840.0K | ||||
| Trade And Other Current Payables | $3.1M | $2.5M | $3.3M | $6.4M | $4.6M | |||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $10.0K | $535.0K | $16.0K | $21.0K | $34.0K | $16.0K | ||||
| Noncurrent Liabilities | $1.5M | $25.9M | $69.4M | $16.3M | $18.3M | |||||
| Noncurrent Assets | $25.9M | $27.1M | $33.2M | $56.0M | $32.8M | |||||
| Current Liabilities | $24.7M | $12.5M | $8.6M | $29.9M | $16.2M | |||||
| Current Assets | $62.1M | $99.3M | $29.7M | $30.4M | $34.5M | |||||
| Warrant Liability | $8.3M | $50.8M | $131.0K | $1.0M | $1.3M | |||||
| Retained Earnings Accumulated Deficit | -$501.0M | -$462.9M | -$419.6M | -$404.6M | ||||||
| Property Plant And Equipment Net | $137.0K | $257.0K | $405.0K | $551.0K | ||||||
| Prepaid Expense And Other Assets Current | $2.5M | $2.2M | $5.2M | $5.4M | ||||||
| Other Noncurrent Liabilities | $182.0K | $80.0K | $62.0K | $44.0K | $34.0K | |||||
| Other Liabilities Noncurrent | $661.0K | $565.0K | $764.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $46.6M | $54.2M | $60.1M | -$72.5M | $78.7M | $42.8M | $54.7M | $49.7M | $44.4M |
| Liabilities | $7.0M | $8.5M | $8.2M | $16.2M | $17.5M | $13.1M | |||
| Assets | $53.6M | $62.6M | $68.3M | $88.7M | $96.1M | $55.9M | |||
| Equity | $46.6M | $54.2M | $60.1M | -$72.5M | $78.7M | $42.8M | $54.7M | $49.7M | $44.4M |
| Cash And Cash Equivalents | |||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $48.7M | $56.1M | $62.5M | $80.5M | $87.4M | $48.7M | $62.5M | $53.0M | $59.8M |
| Intangible Assets Other Than Goodwill | |||||||||
| Property Plant And Equipment | |||||||||
| Retained Earnings | |||||||||
| Cash Flows From Used In Operating Activities | |||||||||
| Cash Flows From Used In Investing Activities | |||||||||
| Cash Flows From Used In Financing Activities | |||||||||
| Adjustments For Increase Decrease In Trade And Other Payables | |||||||||
| Adjustments For Decrease Increase In Trade And Other Receivables | |||||||||
| Trade And Other Current Payables | |||||||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | |||||||||
| Noncurrent Liabilities | |||||||||
| Noncurrent Assets | |||||||||
| Current Liabilities | |||||||||
| Current Assets | |||||||||
| Warrant Liability | |||||||||
| Retained Earnings Accumulated Deficit | -$493.7M | -$486.6M | -$472.0M | -$455.8M | -$440.8M | -$428.6M | |||
| Property Plant And Equipment Net | $174.0K | $218.0K | $247.0K | $315.0K | $338.0K | $360.0K | |||
| Prepaid Expense And Other Assets Current | $2.7M | $2.5M | $2.5M | $3.8M | $4.5M | $3.2M | |||
| Other Noncurrent Liabilities | |||||||||
| Other Liabilities Noncurrent | $652.0K | $352.0K | $325.0K | $568.0K | $536.0K | $513.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | -$38.1M | $72.0M | $7.9M | -$8.3M | -$25.0M | -$2.2M | |||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $145.0K | -$1.2M | -$769.0K | -$349.0K | -$41.0K | -$1.4M | |||
| Payments For Share Issue Costs | $234.0K | $1.3M | $761.0K | $8.0K | $730.0K | ||||
| Share Based Compensation | $7.6M | $7.4M | $4.9M | $4.8M | |||||
| Payments To Acquire Intangible Assets | $300.0K | $699.0K | $419.0K | $0.00 | |||||
| Payments Of Lease Liabilities Classified As Financing Activities | $937.0K | $692.0K | $2.1M | $2.2M | |||||
| Net Cash Provided By Used In Operating Activities | -$31.0M | -$32.8M | -$21.1M | -$48.8M | |||||
| Net Cash Provided By Used In Investing Activities | -$20.0K | -$699.0K | -$419.0K | $2.0M | |||||
| Net Cash Provided By Used In Financing Activities | $327.0K | $46.1M | $8.0M | $200.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | |||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | |||
| Payments For Share Issue Costs | |||
| Share Based Compensation | $2.3M | $2.1M | $1.6M |
| Payments To Acquire Intangible Assets | $300.0K | $700.0K | $419.0K |
| Payments Of Lease Liabilities Classified As Financing Activities | |||
| Net Cash Provided By Used In Operating Activities | -$8.3M | -$8.0M | -$9.2M |
| Net Cash Provided By Used In Investing Activities | -$320.0K | -$700.0K | -$419.0K |
| Net Cash Provided By Used In Financing Activities | $422.0K | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 797.1M | 739.6M | 659.5M | 603.2M |
| Weighted Average Number Of Diluted Shares Outstanding | 797.1M | 739.6M | 659.5M | 603.2M |
| Earnings Per Share Diluted | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
| Earnings Per Share Basic | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 799.9M | 799.4M | 784.3M | 770.1M | 770.1M | 700.3M | 685.0M | 628.4M | 623.9M |
| Weighted Average Number Of Diluted Shares Outstanding | 799.9M | 799.4M | 784.3M | 770.1M | 770.1M | 700.3M | 685.0M | 628.4M | 623.9M |
| Earnings Per Share Diluted | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 | $0.00 | $-0.02 |
| Earnings Per Share Basic | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 | $0.00 | $-0.02 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $7.6M | $7.4M | $4.9M | $4.8M | |||||
| Investment Income Interest | $2.2M | $3.0M | $2.1M | $840.0K | |||||
| Gain Loss On Derivative Instruments Net Pretax | $805.0K | -$419.0K | $245.0K | $9.3M | |||||
| Foreign Currency Transaction Gain Loss After Tax | -$6.3M | $1.2M | -$2.3M | $2.7M | |||||
| Other Reserves | $7.4M | $7.4M | $5.0M | $7.0M | $7.0M | $7.0M | |||
| Interest Received Classified As Investing Activities | $696.0K | $1.0K | $44.0K | $377.0K | $286.0K | $1.1M | |||
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | $1.5M | -$954.0K | -$1.8M | $483.0K | -$44.0K | -$1.4M | |||
| Finance Income | $696.0K | $1.0K | $44.0K | $377.0K | $307.0K | $827.0K | |||
| Finance Costs | $3.4M | $4.0M | $6.4M | $4.4M | $3.8M | $1.1M | |||
| Administrative Expense | $19.5M | $15.9M | $21.2M | $15.9M | $11.8M | $10.7M | |||
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$2.1M | $954.0K | $1.8M | -$483.0K | $44.0K | $1.4M | |||
| Adjustments For Sharebased Payments | $3.9M | $3.3M | $1.6M | $1.6M | $2.2M | $3.7M | |||
| Adjustments For Finance Costs | $2.9M | $3.8M | $6.2M | $4.6M | $3.8M | $1.1M | |||
| Adjustments For Depreciation And Amortisation Expense | $727.0K | $642.0K | $1.6M | $1.6M | $39.0K | $36.0K | |||
| Depreciation | $157.0K | $143.0K | $171.0K | $181.0K | |||||
| Share Premium | $254.3M | $247.5M | $161.8M | $121.7M | $118.5M | ||||
| Issued Capital | $1.9M | $1.8M | $1.0M | $294.0K | $214.0K | ||||
| Current Provisions | $4.8M | $2.8M | $418.0K | $309.0K | $332.0K | ||||
| Current Prepayments | $3.1M | $2.8M | $1.6M | $2.1M | $1.1M | ||||
| Capital Reserve | $132.7M | $129.8M | $128.4M | $59.1M | $18.6M | ||||
| Accruals | $4.5M | $3.8M | $4.2M | $5.1M | $4.4M | ||||
| Treasury Shares | 1.1M | 1.1M | 1.3M | 1.3M | 307.0K | ||||
| Reclassification Adjustments On Exchange Differences On Translation Net Of Tax | $1.8M | $191.0K | -$349.0K | $499.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.7M | $2.1M | $2.3M | $1.7M | $2.1M | $2.1M | $1.5M | $943.0K | $1.6M |
| Investment Income Interest | $504.0K | $589.0K | $659.0K | $983.0K | $559.0K | $617.0K | $689.0K | $373.0K | $306.0K |
| Gain Loss On Derivative Instruments Net Pretax | $196.0K | -$101.0K | $416.0K | -$59.0K | -$69.0K | -$448.0K | $0.00 | -$102.0K | $542.0K |
| Foreign Currency Transaction Gain Loss After Tax | $1.9M | -$5.3M | -$2.8M | -$6.4M | $31.0K | $613.0K | $2.5M | -$803.0K | -$1.2M |
| Other Reserves | |||||||||
| Interest Received Classified As Investing Activities | |||||||||
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | |||||||||
| Finance Income | |||||||||
| Finance Costs | |||||||||
| Administrative Expense | |||||||||
| Adjustments For Unrealised Foreign Exchange Losses Gains | |||||||||
| Adjustments For Sharebased Payments | |||||||||
| Adjustments For Finance Costs | |||||||||
| Adjustments For Depreciation And Amortisation Expense | |||||||||
| Depreciation | $38.0K | $100.0K | $100.0K | $41.0K | $100.0K | $100.0K | $42.0K | ||
| Share Premium | |||||||||
| Issued Capital | |||||||||
| Current Provisions | |||||||||
| Current Prepayments | |||||||||
| Capital Reserve | |||||||||
| Accruals | |||||||||
| Treasury Shares | |||||||||
| Reclassification Adjustments On Exchange Differences On Translation Net Of Tax |
Most recent annual filing with the SEC: March 19, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.